wang xiaotong

Mrs. wang xiaotong

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
CSChen Shen
Chen Shen
DLDeze Li
Deze Li
WXwang xiaotong
wang xiaotong
YSYang Sun
Yang Sun
HZHuiwen Zheng
Huiwen Zheng
SZShunying Zhao
Shunying Zhao
Background: Severe Mycoplasma pneumoniae pneumonia (SMPP) presents with heterogeneous clinical complications and imaging manifestations, including pleural effusion (PE), bronchiolitis obliterans (BO), and distinct imaging/bronchoscopic phenotypes. The precise systemic immune subpopulation dynamics underlying these distinct phenotypes remain poorly defined. Methods: We conducted flow cytometric profiling of peripheral blood mononuclear cells (PBMCs) from pediatric patients to compare mild MPP (MMPP-N) and severe MPP subtypes. SMPP patients were stratified into subgroups including those with BO (SMPP&BO, n = 3), PE (SMPP&PE), and three imaging/bronchoscopic phenotypes: Group A (SMPP-GA, mucous plugs), Group B (SMPP-GB, mucosal necrosis), and Group C (SMPP-GC, diffuse bronchiolitis). Composite immune indices and multi-marker discriminant analysis were constructed for secondary analysis. Results: Comprehensive high-dimensional profiling suggested that a fundamental innate-adaptive immune rebalancing may represent a key pathophysiological axis in severe disease. Patients with PE exhibited massive CD16− monocyte expansion (Delta = 40.0%) coupled with CD8+ Teff collapse (Delta = −9.2%). Preliminary data also suggest BO may be marked by CD56−CD11C+ monocyte depletion (Delta = −23.1%, n = 3), warranting further validation. Imaging subgroup profiling revealed that SMPP-GC featured major B-cell maturation alterations (HLADR+CD45RAhigh expansion and CD38+CD25low depletion). Composite indices including the Adaptive Exhaustion Score suggested discriminatory power (AUC = 0.90 for PE vs. uncomplicated SMPP). The Innate-Adaptive Ratio increased progressively with severity (Spearman rho = +0.40, p = 0.0002). Conclusions: SMPP is not immunologically uniform. Innate-adaptive rebalancing underlies complication-specific phenotypes: inflammatory monocyte mobilization with adaptive exhaustion is strongly associated with PE, whereas B-cell maturation alterations characterize diffuse bronchiolitis. These findings identify potential biomarker candidates for patient stratification, though small-cohort observations require extensive validation in larger prospective studies.

28 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CSChen Shen
Chen Shen
WXwang xiaotong
wang xiaotong
Background: Childhood and adolescent cancer mortality has declined for three decades, yet whether the COVID-19 pandemic interrupted this decline has never been quantified at the population level; the official Global Burden of Disease (GBD) 2023 childhood cancer analysis does not examine the 2019–2021 window. We analyzed the 0–19-year neoplasm burden in GBD 2023 with explicit attention to the pandemic window.Methods: We extracted deaths and incident cases for the GBD Level-2 cause “Neoplasms”—an envelope of malignant, benign and in-situ tumors—at ages 0–19 years, both sexes, 1990–2023, globally, for 21 regions and five Socio-demographic Index (SDI) quintiles. We computed crude rates on back-calculated populations, long-term estimated annual percentage changes (EAPCs), and pandemic-window changes with Monte Carlo-propagated uncertainty intervals (UIs); a mortality-to-incidence (M/I) ratio served as a comparative detection-and-survival proxy. Same-pipeline pediatric tuberculosis and lower respiratory infection series provided internal controls. Because approximately 96% of incident cases are benign or in-situ tumors, incidence-side and M/I absolute values are interpreted comparatively only; all primary inference is mortality-based.Results: In 2023, neoplasms caused 148,436 deaths (95% UI 139,201–157,671) at ages 0–19 years, 26.6% fewer than in 1990—versus 144,000 (131,000–162,000) in the official malignant-only analysis, whose intervals fully overlap ours. Reversing three decades of decline, deaths rose 4.7% (−3.3 to +13.5) between 2019 and 2021 to 152,553, the highest since 2008; the rise was broadly graded by development (high-SDI −2.1% to low-SDI +7.9%) and had not fully receded by 2023. Mortality declined slowest among comparator diseases (EAPC −1.61 versus tuberculosis −3.96 and lower respiratory infections −3.89); the neoplasm-to-tuberculosis death ratio crossed over from 0.78 to 1.69. The low-to-high-SDI M/I gap widened from 14.5-fold to 21.7-fold. Adolescents aged 15–19 years became the largest mortality band among ages 5–19 years—nearly level with the under-5 band (41,182 versus 42,222 deaths)—and rose most of any band over 2019–2023 (+8.0%), while under-5 deaths fell 6.3%. Interrupted time series analysis formally confirmed the mortality reversal: at the BIC-optimal intervention year of 2019, the global mortality series showed an immediate level increase of 7.5% (95% CI 2.4 to 12.9), with 2023 mortality 15.8% (10.7 to 21.2) above the counterfactual pre-pandemic trend.Interpretation: The pandemic window marks a fault line in pediatric cancer control: a development-graded mortality reversal superimposed on a widening survival divide. Because GBD 2023 mortality models incorporate pandemic-period covariates, we present this as a data-and-model signal requiring triangulation, not a pure causal claim. Reaching the WHO childhood cancer survival targets requires closing the diagnostic-treatment gap the pandemic exposed.

28 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CSChen Shen
Chen Shen
WXwang xiaotong
wang xiaotong
HCHao Chen
Hao Chen
DLDeze Li
Deze Li
Background: Retinoblastoma is the most common primary intraocular malignancy of childhood and is nearly universally curable where effective services exist: three-year survival is 99.5% in high-income countries versus 57.3% in low-income countries. Because its occurrence is largely non-modifiable while its outcome is highly treatment-dependent, retinoblastoma is among the most sensitive tracers of childhood cancer cure capacity. We quantified its global burden, trends, and diagnosis–outcome gap. Methods: We analysed Global Burden of Disease (GBD) Study 2023 estimates (results release v8352) for retinoblastoma (cause_id 1009). Deaths and incident cases at ages 0–19 years — the sum of the <5, 5–9, 10–14, and 15–19-year bands — were extracted for the global level, 21 regions, and five Socio-demographic Index (SDI) quintiles over 1990–2023, with a national map for 204 countries in 2022. The mortality-to-incidence ratio (M/I) served as a proxy for cure. Reporting follows GATHER. Results: In 2023, retinoblastoma caused 3,226 deaths (95% uncertainty interval [UI] 1,493–6,569) at ages 0–19 years, down 31.8% from 1990; the crude death rate declined significantly (estimated annual percentage change [EAPC] −1.48% per year, 95% CI −1.60 to −1.36), while the incident case count rose significantly (EAPC +0.63%, 95% CI 0.40 to 0.87). The global M/I fell from 87.4% to 55.5%, yet the low-to-high SDI M/I ratio widened from 3.1-fold to 13.0-fold — the widest disparity among 14 childhood cancers by point estimate (95% UI 3.02–39.65). Children under 5 years accounted for 87.7% of deaths (95% UI 67.1–96.1). The cross-SDI mortality gradient (18.8-fold) far exceeded the incidence gradient (1.5-fold). Conclusions: Residual retinoblastoma mortality is concentrated almost entirely in children under 5 years in low-SDI settings and is consistent with an outcome-driven divide rooted in diagnostic delay and treatment access. Community-level recognition of leukocoria offers the highest-leverage intervention, and the M/I provides a measurable indicator for monitoring the WHO Global Initiative for Childhood Cancer.

28 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
HCHao Chen
Hao Chen
DLDeze Li
Deze Li
WXwang xiaotong
wang xiaotong
CSChen Shen
Chen Shen
Mycoplasma pneumoniae pneumonia (MPP) has re-emerged globally since 2023, with macrolide-resistant M. pneumoniae (MRMP) exceeding 80% of isolates in China and the Republic of Korea; because tetracyclines and fluoroquinolones are age-restricted in children, no guideline-endorsed antibiotic class outside Japan combines reliable activity against resistant strains with an unrestricted pediatric safety profile. Macrolide resistance prolongs fever and hospitalization without worsening severity, implicating dysregulated host inflammation in the residual burden. We derived an MPP host disease signature from public pediatric transcriptomes and prioritized approved compounds through four executed evidence layers: pathway enrichment, network proximity, LINCS L1000 signature reversal, and literature triangulation. Re-analysis of the largest MPP blood cohort identified 159 differentially expressed genes, and the age-adjusted MPP-versus-viral model reproduced the published signature (2,976 shared genes, 99.8% concordance). The target map converges on NLRP3-IL-1β-pyroptosis and JAK-STAT axes, with a transcriptome-supported AIM2 signal; doxycycline (z = -3.81) was significantly proximal to the disease module, whereas quercetin (z = -3.03) is discounted for annotation-density artifacts. Corticosteroids anchor Tier 1, and JAK inhibitors are the highest-priority testable hypothesis. This hypothesis-generating framework provides a reproducible template for host-directed repurposing in antimicrobial-resistant pediatric respiratory infections.

12 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
HJHao Jing
Hao Jing
HCHao Chen
Hao Chen
WXwang xiaotong
wang xiaotong
DLDeze Li
Deze Li
CSChen Shen
Chen Shen
Background. Haemophilus influenzae (Hi) is a common commensal of the pediatric respiratory tract and a lower-respiratory pathogen frequently detected in Henoch–Schönlein purpura (HSP, IgA vasculitis). Pathogenicity is largely capsule-determined, but the relationship between Hi capsular type and disease phenotype in children remains unclear. Methods. Detection rates were analyzed in a single-center cohort of 11,017 children who underwent bacterial nucleic-acid testing (HSP 2,596; other respiratory diseases 8,382; 39 with other respiratory diagnoses not entered into the comparisons), with 39 concurrently examined healthy children tested by the same assay as an external reference group. Hi-positive specimens were capsular-typed by an in-house two-step qPCR (bexA screening, then Region II multiplex, a–f). Associations were estimated by logistic regression with complementary age-confounding control and immune-status/testing-intensity sensitivity analyses; pathogenic potential was profiled in 44 reference genomes. Results. Hi detection was higher in HSP than in other respiratory diseases (57.0% vs 11.4%; adjusted OR 9.8, 95%CI 8.7–11.1) and healthy children (12.8%), consistent across age-handling methods and immune-normal subsets (ORs 7.8–9.8), and HSP-specific rather than severity-related. Capsular type spectra differed: HSP was relatively enriched for encapsulated type c (~50% vs 75–80% NTHi; OR 2.68–3.87). In pneumonia, NTHi patients were younger (median 3 vs 8 years) and more pneumonia-prone (74% vs 18%). Genomic pathogenic potential stratified by capsule; NTHi retained a rich virulence-factor repertoire. Conclusions. Respiratory Hi is highly detected in pediatric pneumonia and HSP, with distinct capsular type spectra and clear type–phenotype associations, consistent with capsule-dependent disease tropism. These associations are hypothesis-generating and require mechanistic validation.

3 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
WXwang xiaotong
wang xiaotong
HCHao Chen
Hao Chen
DLDeze Li
Deze Li
CSChen Shen
Chen Shen
Tissue-resident macrophage diversity has been mapped at the gene-expression level, and alternative splicing has been catalogued across immune lineages [1,2]; isoform behavior along the monocyte-to-macrophage differentiation axis remains unexamined. Analyzing a 17-gene immune panel across BLUEPRINT differentiation series and GTEx v8, we identify an MSR1 isoform switch with complete donor-level separation (short-isoform fraction 0.844–0.914 in monocytes versus 0.291–0.541 in six macrophage samples; exact permutation p = 0.024) — a switch from the dominant-negative SR-AIII scavenger-receptor isoform to functional SR-AI/II receptors — with equally supported PTPRC, MYD88, and IRAK1 remodeling, whereas an IL1B canonical-fraction rise is donor-heterogeneous (p = 0.114). LY96 (MD-2) is induced ~17-fold during differentiation, yet the functionally decisive antagonist/agonist isoform ratio is not resolved by standard short-read annotation — a methodological gap for immune isoform studies. CD14/CD163 show dosage regulation without isoform switching: CD163 peaks in LPS-driven M1 macrophages and, in human brain, marks border-associated macrophages rather than microglia. A 62-gene cytoskeletal panel nominates septin-family isoform divergence as a candidate mechanism of the ramified-to-amoeboid morphology spectrum, with PTBP1/hnRNP/SRSF programs as candidate executors of immune-side switching. Differentiation-coupled isoform remodeling is thus a component of macrophage identity.